Long non‐coding RNAs as key regulators of neurodegenerative protein aggregation

by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia

Abstract The characteristic events in neurodegenerative diseases (NDDs) encompass protein misfolding, aggregation, accumulation, and their related cellular dysfunction, synaptic function loss. While distinct proteins are implicated in the pathological processes of...

Tracer kinetic model detecting heterogeneous blood–brain barrier permeability to water and contrast agent in Alzheimer’s disease and dementia with Lewy bodies

by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia

Abstract INTRODUCTION Blood–brain barrier (BBB) breakdown is essential in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), whereas the variability in BBB permeability to water and contrast agent is less clear. METHODS We investigated BBB...

Identifying gait differences between Alzheimer’s disease and dementia with Lewy bodies and their associations with regional amyloid deposition

by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia

Abstract INTRODUCTION We aimed to compare gait between individuals with Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and cognitively unimpaired (CU) individuals and to evaluate the association between gait and regional amyloid beta (Aβ) burden in...

Prevalence of subjective cognitive decline and its association with physical health problems among urban community dwelling elderly population in South India

by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia

Abstract INTRODUCTION No studies in India have explored subjective cognitive decline (SCD), a hallmark of stage II of preclinical Alzheimer’s disease. This study aims to assess the prevalence and correlates of SCD in a South Indian, urban, elderly population....

SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer’s disease

by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia

Abstract INTRODUCTION Tau pathology impacts neurodegeneration and cognitive decline in Alzheimer’s disease (AD), with the dorsal raphe nucleus (DRN) being among the brain regions showing the earliest tau pathology. As a serotonergic hub, DRN activity is altered...

Massive changes in gene expression and their cause(s) can be a unifying principle in the pathobiology of Alzheimer’s disease

by Clinical Neuropsychologist | Thursday, February 6, 2025 | Dementia

Abstract Understanding of the biology of Alzheimer’s disease (AD) has long been fragmented, with various investigators concentrating on amyloid beta (Aβ) or tau, inflammation, cell death pathways, misfolded proteins, glia, and more. Yet data from multiple...